权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Gentoxic Estrogen Ratio: A Novel Estrogen Biomarker and Breast Cancer Risk

生殖毒性雌激素比率：一种新型雌激素生物标志物和乳腺癌风险

基本信息

批准号：
8721901
负责人：
Kerryn W Reding
金额：
$ 17.04万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-08-15 至 2017-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8721901
关键词：
Address Adult Area Base Pairing Benzene Binding Biological Assay Biological Markers Breast Cancer Cell Breast Cancer Prevention Breast Cancer Risk Factor Cancer Patient Cancer cell line Carcinogens Catechol Estrogens Clinical Clinical Data Consumption DNA DNA Adducts Data Development Diagnosis Diet Dietary Component Dietary Factors Dietary Intervention Dietary intake Estrogens Fat-Restricted Diet Food Future Gene Mutation High Risk Woman Hormones Laboratories Lead Measures Methods Metric Modification Monitor Names Nested Case-Control Study Obesity Pathway interactions Performance Pilot Projects Plants Positioning Attribute Postmenopause Prospective Studies ROC Curve Recommendation Research Research Project Grants Resveratrol Risk Risk Estimate Risk Reduction Role Sampling Testing Urine Vegetables Woman Women&apos s Health Work adduct anticancer research base cancer risk cohort cost cost effective dietary supplements experience fruits and vegetables high risk indexing lifestyle factors malignant breast neoplasm novel parity public health relevance research study response

项目摘要

DESCRIPTION (provided by applicant): A large accumulation of data has implicated estrogen in breast cancer (BC) development. The catechol estrogen pathway has been a focus of BC research because particular catechol estrogen metabolites are genotoxic. That is, these estrogen metabolites are capable of forming DNA adducts which may lead to DNA mutations in a manner similar to benzene, a known carcinogen. The GER assay provides information on the proportion of estrogen metabolites that are bound to DNA base pairs in the urine in relation to unbound estrogen metabolites, thereby quantifying the extent to which estrogen metabolites have removed base pairs from the DNA. Our laboratory colleagues observed in 2 small-scale studies that GER was higher in BC patients and healthy women at high risk of BC compared to low-risk, healthy controls. While these studies support the hypothesis that BC development is influenced by GER, these data require replication in a large, prospective study. Methods: We propose to conduct a nested case-control study within the WHI cohort using urine samples collected prior to diagnosis from 360 BC cases and 360 matched controls in order to examine the risk of BC associated with GER (Specific Aim 1) and investigate whether dietary intake is associated with GER (Specific Aim 2). Our secondary aims involve exploring the presence of effect modifiers in the pathway involving GER, dietary factors, and BC (Secondary Aim 1) and examine whether a reduced set of estrogen metabolites are equally predictive of BC risk as the current 38 metabolites comprising the GER (Secondary Aim 2). Summary: The proposed study would be the first study using prospectively-collected samples examining the risk of BC in relation to this novel, estrogen biomarker. Leveraging the existing data from a top-rate study, such as WHI, provides an efficient method for addressing the research gaps surrounding GER. Our experienced, multi-disciplinary research team is well suited to carry out this important research project. Data emanating from this proposal could inform on the utility of the GER biomarker in relation to breast cancer.

描述(由申请人提供)：大量的数据积累表明雌激素与乳腺癌(BC)的发展有关。儿茶酚雌激素途径一直是BC研究的重点，因为特定的儿茶酚雌激素代谢产物具有遗传毒性。也就是说，这些雌激素代谢物能够形成DNA加合物，这可能会导致DNA突变，其方式类似于已知的致癌物质苯。GER分析提供了与尿中DNA碱基对结合的雌激素代谢物与未结合的雌激素代谢物的比例信息，从而量化了雌激素代谢物从DNA中去除碱基对的程度。我们的实验室同事在两项小规模研究中观察到，与低风险的健康对照组相比，BC患者和高风险的健康女性的GER更高。虽然这些研究支持BC的发育受GER影响的假设，但这些数据需要在一项大型的前瞻性研究中重复。方法：我们建议在WHI队列中进行嵌套式病例对照研究，使用诊断前收集的360例BC患者和360名匹配对照的尿样，以检查BC与GER相关的风险(特定目标1)，并调查饮食摄入是否与GER相关(特定目标2)。我们的次要目标包括探索在涉及GER、饮食因素和BC(次要目标1)的途径中是否存在效应修饰物，并检查减少的雌激素代谢物集合是否与目前组成GER(次要目标2)的38种代谢物一样预测BC风险。摘要：这项拟议的研究将是第一次使用前瞻性收集的样本来检验与这一新的雌激素生物标记物有关的BC的风险。利用来自一流研究的现有数据，如WHI，为解决围绕GER的研究空白提供了一种有效的方法。我们经验丰富的多学科研究团队非常适合开展这一重要研究项目。从这项建议中得出的数据可以为GER生物标记物在乳腺癌中的应用提供信息。